Stefan Hart - Concepedia

Author

Stefan Hart

Max Planck Institute of Biochemistry

Also Known As

S Hart, S. Hart, S.R. Hart, Stefan Hart

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

Max Planck Institute of Biochemistry National University Cancer Institute, Singapore Singapore Science Park Max Planck Society National University of Singapore

About

Stefan Hart is an author at Max Planck Institute of Biochemistry specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	1.4K
2	Natural Sciences	2	2	225
3	Biochemistry	2	2	163
4	Engineering	1	1	31
5	Health Sciences	1	1	150

Stefan Hart

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor Stefan Hart, Oliver M. Fischer, Axel Ullrich Cancer Research	2004	287
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies Stefan Hart, K C Goh, Veronica Novotny‐Diermayr, Leukemia	2011	195
Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma Anthony D. William, Angeline C.-H. Lee, Stéphanie Blanchard, Journal of Medicinal Chemistry Janus Kinase 2PharmacotherapyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2011	194
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention Han Kiat Ho, Sharon Pok, Sylvia Streit, Journal of Hepatology HepatologyAlpha-fetoprotein SecretionHepatocellular CarcinomaPathologyHepatocellular Carcinoma Progression	2008	190
Oxidative and Osmotic Stress Signaling in Tumor Cells Is Mediated by ADAM Proteases and Heparin-Binding Epidermal Growth Factor Oliver M. Fischer, Stefan Hart, Andreas Gschwind, Molecular and Cellular Biology Environmental StressTyrosine KinaseImmunologyCell DeathCell Proliferation	2004	150
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes Anas Younes, Jorge Romaguera, Michelle A. Fanale, Journal of Clinical Oncology	2012	139
SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer Veronica Novotny‐Diermayr, Kanda Sangthongpitag, Chang Hu, Molecular Cancer Therapeutics Liquid TumorsHigh Tumor ExposureOncologyBiochemistryMedicine	2010	132
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties K C Goh, Veronica Novotny‐Diermayr, Stefan Hart, Leukemia MedicineReceptor Tyrosine KinaseMalignant Blood DisorderImmunologyPotent Anti-leukemic Properties	2011	128
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia Stefan Hart, K. C. Goh, Veronica Novotny‐Diermayr, Blood Cancer Journal ImmunologyPharmacotherapyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2011	106
GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways Stefan Hart, Oliver M. Fischer, Norbert Prenzel, Biological Chemistry	2005	101

Page 1